Ping An Good Doctor unveils pharma partnerships at CIIE 2025 to advance digital health

Ping An Good Doctor strengthened its position in China’s digital healthcare landscape this week with a series of new strategic cooperation agreements unveiled at the 8th China International Import Expo (CIIE) in Shanghai.

The company signed partnerships with several major pharmaceutical players, each aimed at accelerating innovation and improving patient access to integrated digital healthcare services.

Under the agreement with 斯利安药业 Pharmaceutical, PAGD will co-develop a full-chain maternal and infant health support system. The initiative brings together professional maternal–infant products with digital health services, creating a unified solution for families seeking reliable guidance at every stage of care.

A second partnership with Mabwell focuses on building an integrated, whole-course disease management ecosystem in the fields of bone health and autoimmune diseases. The two companies aim to streamline diagnosis, treatment, and long-term management through a blend of clinical expertise and digital tools.

Meanwhile, the collaboration with Trinomab will establish a shared resource platform designed to improve health education and engagement among patients, physicians, and corporate clients. The platform will strengthen communication across the healthcare value chain while supporting more informed decision-making.

Ping An Good Doctor said these partnerships reflect its commitment to empowering pharmaceutical companies with digital solutions that more precisely target and meet patient needs. The company aims to provide “worry-free, time-saving, and cost-saving” services for families across China as it continues to expand its healthcare ecosystem.